Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Nykode Therapeutics Investigates Cancer Vaccine Combined with Tecentriq in HPV16-Positive Cervical Cancer

NextEdge Admin

16 Apr 2024

2 min 15 sec

Nykode Therapeutics initiated a Phase II trial for its cancer vaccine, VB10.16, aimed at treating HPV16-positive, PD-L1-positive, recurrent or metastatic cervical cancer. The trial, conducted in collaboration with Roche’s checkpoint inhibitor Tecentriq (atezolizumab), focuses on patients whose cancer is resistant to first-line treatment with Merck’s Keytruda plus chemotherapy and Genentech’s Avastin.

The trial consists of two arms: one evaluating VB10.16 with a placebo, and the other studying VB10.16 combined with Tecentriq. Initially, each arm will enroll approximately 30 patients in a double-blind study to compare the efficacy of the treatments. Subsequently, the more effective treatment will be selected for further investigation in an additional 70 patients to assess safety and efficacy.

Klaus Edvardsen, Nykode’s chief development officer, expressed optimism based on previous trials’ positive outcomes, highlighting VB10.16’s promising clinical profile and tolerability when combined with atezolizumab. Nykode, headquartered in Oslo, Norway, is conducting the trial in collaboration with the nonprofit Gynecologic Oncology Group Foundation.

Nykode’s pipeline includes ongoing trials of VB10.16 in HPV16-positive cervical cancer, high-grade squamous intraepithelial lesion of the cervix, and head and neck cancer. Additionally, they are developing an individualized therapeutic cancer vaccine, VB10.NEO, in partnership with Genentech, currently undergoing evaluation in advanced cancers.

This Phase II trial underscores Nykode’s commitment to advancing innovative immunotherapy solutions for HPV16-positive cancers, leveraging strategic collaborations and a diversified pipeline to address unmet medical needs in oncology.